List of works - Brian D. Lehmann

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

scientific article published on 12 May 2015

A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer

scientific article

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

scientific article published on 18 March 2007

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer

scientific article published on 4 May 2015

Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes

scientific article published on 31 August 2021

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

scientific article published on 21 February 2008

Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2

scientific article

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

scientific article

Clinical implications of molecular heterogeneity in triple negative breast cancer.

scientific article

Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control

scientific article published on 4 November 2013

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells

scientific article published on August 2011

Detection of internal exon deletion with exon Del.

scientific article

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

scientific article published on 15 August 2013

Distinct roles for p107 and p130 in Rb-independent cellular senescence

scientific article

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies

scientific article published on 26 May 2016

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

scientific article published on 26 March 2015

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

scientific article

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

scientific article

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

scientific article (publication date: July 2011)

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer

scientific article published on 2 April 2013

Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer

scientific article

Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data.

scientific article

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

scientific article published on 19 December 2013

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

scientific article published on 01 November 2021

Multi-perspective quality control of Illumina exome sequencing data using QC3.

scientific article

New strategies for triple-negative breast cancer--deciphering the heterogeneity

scientific article published on February 2014

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

scientific article

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

scientific article published on 22 January 2013

Practicality of identifying mitochondria variants from exome and RNAseq data.

scientific article published on 23 October 2015

RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining

scientific article

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

scientific article

RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library

scientific article published on 12 October 2015

Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

scientific article

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

scientific article

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

scientific article

SPARCL1 suppresses metastasis in prostate cancer.

scientific article published on 20 July 2013

Senescence-associated exosome release from human prostate cancer cells.

scientific article published on October 2008

Subtyping of triple-negative breast cancer: implications for therapy

scientific article

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

scientific article published on 10 March 2008

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

scientific article

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

scientific article published on 01 March 2020

Targeting mutant p53 in human tumors

scientific article published on 10 September 2012

Targeting prostate cancer based on signal transduction and cell cycle pathways.

scientific article published on 16 June 2008

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

scientific article published on 26 March 2007

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

scientific article

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

scientific article published on January 2015

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

scientific article published on 27 November 2012

List of works by Brian D. Lehmann

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer

Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

Clinical implications of molecular heterogeneity in triple negative breast cancer.

Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells

Detection of internal exon deletion with exon Del.

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

Distinct roles for p107 and p130 in Rb-independent cellular senescence

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer

Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer

Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Multi-perspective quality control of Illumina exome sequencing data using QC3.

New strategies for triple-negative breast cancer--deciphering the heterogeneity

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

Practicality of identifying mitochondria variants from exome and RNAseq data.

RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library

Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

SPARCL1 suppresses metastasis in prostate cancer.

Senescence-associated exosome release from human prostate cancer cells.

Subtyping of triple-negative breast cancer: implications for therapy

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

Targeting mutant p53 in human tumors

Targeting prostate cancer based on signal transduction and cell cycle pathways.

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.